Payment overview · 2025
General Payments
$840.75
26 reported records · 7 companies
Healthcare provider profile · identity verified
Jonathan Selzer, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BRONX, NY · NPI 1265404271
Verified facts
What the public records show
CMS Open Payments records show Jonathan Selzer, MD received $840.75 in general payments during 2025 across 26 reported records.
Intra-Sana Laboratories accounted for 74.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $621.98 | 74.0% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $78.77 | 9.4% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $46.63 | 5.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $36.43 | 4.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.75 | 2.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.50 | 2.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.69 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $840.75 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $621.98 | 16 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $621.98 | 16 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $621.98 | 16 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $78.77 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $78.77 | 3 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $46.63 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $36.43 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 91 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 725 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 539 | 125 |
| Eliquis | Apixaban | 500 | 85 |
| Losartan Potassium | Losartan Potassium | 485 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 370 | 90 |
| Furosemide | Furosemide | 346 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 289 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 284 | 65 |
| Gabapentin | Gabapentin | 283 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 282 | 69 |
| Metformin Hcl | Metformin Hcl | 280 | 68 |
| Omeprazole | Omeprazole | 278 | 69 |
| Lisinopril | Lisinopril | 158 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 48 |
| Montelukast Sodium | Montelukast Sodium | 151 | 46 |
| Januvia | Sitagliptin Phosphate | 148 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 30 |
| Trazodone Hcl | Trazodone Hcl | 142 | 36 |
| Sertraline Hcl | Sertraline Hcl | 133 | 30 |
| Finasteride | Finasteride | 132 | 39 |
| Nifedipine Er | Nifedipine | 122 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 118 | 35 |
| Carvedilol | Carvedilol | 117 | 29 |
| Simvastatin | Simvastatin | 117 | 26 |
| Potassium Chloride | Potassium Chloride | 116 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 28 |
| Xarelto | Rivaroxaban | 98 | 11 |
| Donepezil Hcl | Donepezil Hcl | 95 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 26 |
| Ozempic | Semaglutide | 91 | 16 |
| Topiramate | Topiramate | 83 | 19 |
| Mirtazapine | Mirtazapine | 82 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 74 | 24 |
| Nabumetone | Nabumetone | 74 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 17 |
| Tramadol Hcl | Tramadol Hcl | 70 | 21 |
| Methenamine Hippurate | Methenamine Hippurate | 69 | suppressed |
| Clonazepam | Clonazepam | 64 | 15 |
| Ezetimibe | Ezetimibe | 64 | 19 |
| Azithromycin | Azithromycin | 61 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 17 |
| Midodrine Hcl | Midodrine Hcl | 61 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 18 |
| Memantine Hcl | Memantine Hcl | 60 | 12 |
| Prednisone | Prednisone | 59 | 41 |
| Torsemide | Torsemide | 59 | 18 |
| Valsartan | Valsartan | 59 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 58 | suppressed |
| Famotidine | Famotidine | 57 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 16 |
| Bupropion Xl | Bupropion Hcl | 55 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | suppressed |
| Spironolactone | Spironolactone | 52 | 17 |
| Buspirone Hcl | Buspirone Hcl | 51 | 15 |
| Lorazepam | Lorazepam | 51 | 13 |
| Risperidone | Risperidone | 51 | 17 |
| Telmisartan | Telmisartan | 51 | suppressed |
| Baclofen | Baclofen | 50 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 30 |
| Benztropine Mesylate | Benztropine Mesylate | 48 | suppressed |
| Synthroid | Levothyroxine Sodium | 47 | suppressed |
| Latanoprost | Latanoprost | 46 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | suppressed |
| Trulicity | Dulaglutide | 43 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 42 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 42 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Allopurinol | Allopurinol | 39 | 12 |
| Tradjenta | Linagliptin | 39 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Ramipril | Ramipril | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 36 | 12 |
| Jardiance | Empagliflozin | 36 | suppressed |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | 11 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Nystatin | Nystatin | 32 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Diazepam | Diazepam | 31 | 13 |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 28 | 15 |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Timolol Maleate | Timolol Maleate | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Clotrimazole | Clotrimazole | 24 | suppressed |
| Nyamyc | Nystatin | 24 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 24 | 14 |
| Enulose | Lactulose | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 20 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 20 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 20 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 20 | 15 |
| Synjardy | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 13 |
| Alogliptin | Alogliptin Benzoate | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 19 |
| Glipizide Er | Glipizide | 19 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Repaglinide | Repaglinide | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 12 |
| Atenolol | Atenolol | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 11 |
| Lacosamide | Lacosamide | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 12 |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Nateglinide | Nateglinide | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Levetiracetam Er | Levetiracetam | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $840.75 · 26 records | Intra-Sana Laboratories | CAPLYTA, Dexcom G6 Transmitter, GLYCATE, JARDIANCE, MOUNJARO, Ozempic, RELTONE 200 MG, RELTONE 400 MG, Rybelsus, UZEDY, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error